elacridar

Modify Date: 2024-01-02 21:17:03

elacridar Structure
elacridar structure
 Common Name elacridar
CAS Number 143664-11-3 Molecular Weight 563.643
Density 1.3±0.1 g/cm3 Boiling Point 701.6±60.0 °C at 760 mmHg
Molecular Formula C34H33N3O5 Melting Point 216-218℃
MSDS Chinese USA Flash Point 378.1±32.9 °C

 Use of elacridar


Elacridar is a potent P-glycoprotein (Pgp) and BCRP inhibitor.

 Names

Name N-[4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]phenyl]-5-methoxy-9-oxo-10H-acridine-4-carboxamide
Synonym More Synonyms

 elacridar Biological Activity

Description Elacridar is a potent P-glycoprotein (Pgp) and BCRP inhibitor.
Related Catalog
Target

P-glycoprotein (Pgp), BCRP[1]

In Vitro Elacridar inhibits P-glycoprotein (P-gp) labeling by [3H]azidopine with a IC50 of 0.16 μM[2]. In Caki-1 and ACHN cells, elacridar (2.5 μM) significantly ihibits the cell growth. The P-glycoprotein activity is found to be inhibited by elacridar. The combination of elacridar and sunitinib lead to a significant reduction in ABC Sub-family B Member 2 (ABCG2) expression in 786-O cells[3].
In Vivo Oral co-administration of elacridar (100 mg/kg, p.o.) and crizotinib increases the plasma and brain concentrations and brain-to-plasma ratios of crizotinib in wild-type mice, equaling the levels in Abcb1a/1b; Abcg2-/- mice[1]. In friend leukemia virus stain B mice, the brain-to-plasm partition coefficient (Kp, brain) of elacridar is 0.82, 0.43, and 4.31 after intravenous (2.5 mg/kg), intraperitoneal (100 mg/kg), and oral (100 mg/kg) treatment, respectively[4]. In Mrp4(-/-) mice, elacridar fully inhibits P-gp mediated transport of topotecan, without siginificant effects on Bcrp1-mediated transport[5].
Kinase Assay 10 μL of unlabeled cell membrane suspension (at 0.4 mg of protein/mL) are aliquoted into each well in 96-well plates. 5 μL of GF120918 are then added to each well. The plate is incubated 25 min at 25°C in the dark. 5 μL of tritiated azidopine (1.8 TBq/mmol) (0.6 μM in HCI 0.2 mM) are added to each well. After 25 min of incubation at 25°C in the dark, samples are simultaneously irradiated for 2 min at 254 nm at 0°C with a thin layer chromatography-designed UV lamp directly in contact with the plate. Samples are solubilized in sodium dodecyl sulfate-polyacrylamide gel electrophoresis sample buffer but not heated. After separation on a 7.5% polyacrylamide gel, the gel is treated for fluorography with Amplify and exposed during 3 days onto a photosensitive film. The fluorography is analysed using a Camag thin layer chromatography Scanner II densitometer.
Cell Assay 3.0×103 cells per well are seeded in a 96-well plate. After 24 h incubation, an optimum concentration gradient of elacridar is added to each well. After culturing for 48 h, cell viability is assessed using the proliferation reagent, MTT. Control cells are treated with the vehicle only, 0.1% DMSO. After this final incubation, the medium is aspirated and precipitated formazan crystals are dissolved in DMSO (100 μL/well). The absorbance of each well is measured at 540 nm, and a reference wavelength of 650 nm is read with a multiskan JX microplate reader. Cell viability is calculated as percentage of the control value[3].
Animal Admin Mice are fasted for 3 hr before oral administration of either elacridar (100 mg/kg) or elacridar vehicle. Two hours later, crizotinib (5 mg/kg) is administered to mice orally. Blood and brains are isolated 4 hr after crizotinib oral administration, and processed as described above. The brain concentrations are corrected for the amount of drug in the brain vasculature. Elacridar hydrochloride is dissolved in dimethyl sulfoxide (106 mg/mL) in order to get 100 mg pure elacridar per 1 mL of dimethyl sulfoxide. The stock solution is further diluted with a mixture of Polysorbate 80, ethanol and water [20:13:67 (v/v/v)] to yield a concentration of 10 mg/mL pure elacridar.
References

[1]. Tang SC, et al. Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. Int J Cancer. 2014 Mar 15;134(6):1484-94

[2]. Hyafil F, et al. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res. 1993 Oct 1;53(19):4595-602.

[3]. Sato H, et al. Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells. Eur J Pharmacol. 2015 Jan 5;746:258-66.

[4]. Sane R, et al. Brain distribution and bioavailability of elacridar after different routes of administration in the mouse. Drug Metab Dispos. 2012 Aug;40(8):1612-9.

[5]. de Vries NA, et al. P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan. Clin Cancer Res. 2007 Nov 1;13(21):6440-9.

 Chemical & Physical Properties

Density 1.3±0.1 g/cm3
Boiling Point 701.6±60.0 °C at 760 mmHg
Melting Point 216-218℃
Molecular Formula C34H33N3O5
Molecular Weight 563.643
Flash Point 378.1±32.9 °C
Exact Mass 563.242004
PSA 92.89000
LogP 5.55
Vapour Pressure 0.0±2.2 mmHg at 25°C
Index of Refraction 1.644
Storage condition -20°C Freezer

 Safety Information

Hazard Codes Xi
RIDADR NONH for all modes of transport
RTECS AR7621300

 Articles38

More Articles
Effect of drug efflux transporters on placental transport of antiretroviral agent abacavir.

Reprod. Toxicol. 57 , 176-82, (2015)

Abacavir is as a frequent part of combination antiretroviral therapy used in pregnant women. The aim of this study was to investigate, using in vitro, in situ and ex vivo experimental approaches, whet...

Interaction Studies of Resolvin E1 Analog (RX-10045) with Efflux Transporters.

J. Ocul. Pharmacol. Ther. 31 , 248-55, (2015)

Screening interactions of a resolvin E1 analog (RX-10045) with efflux transporters (P-glycoprotein [P-gp], multidrug resistance-associated protein [MRP2], and breast cancer-resistant protein [BCRP]).M...

Breast Cancer Resistance Protein and P-Glycoprotein Influence In Vivo Disposition of 11C-Erlotinib.

J. Nucl. Med. 56 , 1930-6, (2015)

(11)C-erlotinib is a PET tracer to distinguish responders from nonresponders to epidermal growth factor receptor-targeted tyrosine kinase inhibitors and may also be of interest to predict distribution...

 Synonyms

4-Acridinecarboxamide, N-[4-[2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]-9,10-dihydro-5-methoxy-9-oxo-
N-{4-[2-(6,7-Dimethoxy-3,4-dihydro-2(1H)-isoquinolinyl)ethyl]phenyl}-5-methoxy-9-oxo-9,10-dihydro-4-acridinecarboxamide
N-{4-[2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl]phenyl}-5-methoxy-9-oxo-9,10-dihydroacridine-4-carboxamide
elacridar
GG918
Top Suppliers:I want be here

Get all suppliers and price by the below link:

elacridar suppliers

Price: $79/10mM*1mLinDMSO

Reference only. check more elacridar price

Related Compounds: More...
Elacridar-d4
1189481-51-3
Elacridar HCl
143851-98-3
ELACRIDAR ((2Z)-2-BUTENEDIOATE)
143851-84-7
4-((Cyclohexylamino)methyl)benzoic acid hydrochloride
1158522-08-7
1-[(2,4-Dichlorophenyl)methyl]-N-(1,1-dimethylethyl)-2-methyl-1H-indole-3-methanamine
940364-43-2
2-Methoxy-6-(pyrazol-1-yl)-benzonitrile
134104-43-1
2-[3-Amino-5-({[2-(tert-butoxy)-2-oxoethyl]amino}methyl)-4-methylphenyl]acetic acid
2418678-32-5
1H-3-Benzazepin-7-ol, 8-chloro-2,3,4,5-tetrahydro-5-(3-iodophenyl)-3-methyl-, (S)-
131615-57-1
(4-Methyl-tetrahydro-furan-2-yl)-methanol
6906-52-1
N-(1-cyanocyclopentyl)-2-[4-(4-fluorobenzenesulfonyl)-1,4-diazepan-1-yl]acetamide
930439-75-1
4,5,6,7-Tetrahydrobenzo[d]isoxazole-3-carbaldehyde
1018584-77-4
5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-YL)-8-(trifluoromethyl)quinoline
2813231-50-2
N-(2-Methoxybenzyl)thietan-3-amine
1872962-69-0
Chemsrc provides elacridar(CAS#:143664-11-3) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of elacridar are included as well.>> amp version: elacridar

Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer

Copyright © 2024 ChemSrc All Rights Reserved